Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
Authors
Keywords
-
Journal
Therapeutic Advances in Neurological Disorders
Volume 8, Issue 1, Pages 20-30
Publisher
SAGE Publications
Online
2015-01-07
DOI
10.1177/1756285614564152
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Update on Disease-Modifying Treatments for Multiple Sclerosis
- (2014) Michael D. Carrithers CLINICAL THERAPEUTICS
- Dimethyl Fumarate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
- (2014) Celeste B. Burness et al. CNS DRUGS
- The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
- (2014) Pawel Kawalec et al. Current Neuropharmacology
- Mode of action and clinical studies with fumarates in multiple sclerosis
- (2014) Anke Salmen et al. EXPERIMENTAL NEUROLOGY
- Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE
- (2014) Hui Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
- (2014) Douglas L. Arnold et al. JOURNAL OF NEUROLOGY
- Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study
- (2014) Katrin Strassburger-Krogias et al. Therapeutic Advances in Neurological Disorders
- A Review of Safety-Related Pregnancy Data Surrounding the Oral Disease-Modifying Drugs for Multiple Sclerosis
- (2013) Ellen Lu et al. CNS DRUGS
- Dimethylfumarate: potency prediction and clinical experience
- (2013) David A. Basketter et al. CONTACT DERMATITIS
- BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety
- (2013) Robert J. Fox et al. CURRENT MEDICAL RESEARCH AND OPINION
- Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM
- (2013) Eva Havrdova et al. EXPERT OPINION ON PHARMACOTHERAPY
- Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study
- (2013) Michael Hutchinson et al. JOURNAL OF NEUROLOGY
- Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: The DEFINE study
- (2013) Ludwig Kappos et al. Multiple Sclerosis Journal
- Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study
- (2013) Mariko Kita et al. Multiple Sclerosis Journal
- PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
- (2013) Bob W. van Oosten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Manufacturer's Response to Case Reports of PML
- (2013) Marianne T. Sweetser et al. NEW ENGLAND JOURNAL OF MEDICINE
- PML in a Patient Treated with Fumaric Acid
- (2013) Ummehan Ermis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Case Reports of PML in Patients Treated for Psoriasis
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
- (2011) Ralf A. Linker et al. BRAIN
- Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells
- (2011) Kamran Ghoreschi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study
- (2011) Ludwig Kappos et al. Multiple Sclerosis Journal
- From injection therapies to natalizumab: views on the treatment of multiple sclerosis
- (2011) Roberto Bomprezzi et al. Therapeutic Advances in Neurological Disorders
- Dimethyl fumarate for multiple sclerosis
- (2010) Athina Papadopoulou et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Nicotinic acid– and monomethyl fumarate–induced flushing involves GPR109A expressed by keratinocytes and COX-2–dependent prostanoid formation in mice
- (2010) Julien Hanson et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunotherapy and multiple sclerosis: The devil is in the details
- (2010) D. Bourdette et al. NEUROLOGY
- Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis
- (2009) D. Moharregh-Khiabani et al. Current Neuropharmacology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started